139 related articles for article (PubMed ID: 2285979)
1. Synthesis and structure-activity relationships of human renin inhibitors designed from angiotensinogen transition state.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Etoh Y; Shimaoka I; Tsubaki A; Murakami M; Yamaguchi T
Chem Pharm Bull (Tokyo); 1990 Sep; 38(9):2487-93. PubMed ID: 2285979
[TBL] [Abstract][Full Text] [Related]
2. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of human renin inhibitory peptides, angiotensinogen transition-state analogs containing a retro-inverso amide bond.
Harada H; Iizuka K; Kamijo T; Akahane K; Yamamoto R; Nakano Y; Tsubaki A; Kubota T; Shimaoka I; Umeyama H
Chem Pharm Bull (Tokyo); 1990 Nov; 38(11):3042-7. PubMed ID: 2085885
[TBL] [Abstract][Full Text] [Related]
4. Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Umeyama H; Ishida T; Kiso Y
J Med Chem; 1990 Oct; 33(10):2707-14. PubMed ID: 2120440
[TBL] [Abstract][Full Text] [Related]
5. New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.
Luly JR; Bolis G; BaMaung N; Soderquist J; Dellaria JF; Stein H; Cohen J; Perun TJ; Greer J; Plattner JJ
J Med Chem; 1988 Mar; 31(3):532-9. PubMed ID: 3279206
[TBL] [Abstract][Full Text] [Related]
6. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.
Luly JR; BaMaung N; Soderquist J; Fung AK; Stein H; Kleinert HD; Marcotte PA; Egan DA; Bopp B; Merits I
J Med Chem; 1988 Dec; 31(12):2264-76. PubMed ID: 3143009
[TBL] [Abstract][Full Text] [Related]
7. Renin inhibitors. I. Synthesis and structure-activity relationships of transition-state inhibitors containing homostatine analogues at the scissile bond.
Atsuumi S; Nakano M; Koike Y; Tanaka S; Matsuyama K; Nakano M; Morishima H
Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):364-70. PubMed ID: 1606632
[TBL] [Abstract][Full Text] [Related]
8. Roles of His9 (P2 subsite) and His13 (P3' subsite) in angiotensinogen for catalytic reaction of renin.
Nabi AH; Uddin MN; Nakagawa T; Orihashi T; Ebihara A; Iwasawa A; Nakamura Y; Suzuki F
Int J Mol Med; 2005 Jul; 16(1):103-7. PubMed ID: 15942685
[TBL] [Abstract][Full Text] [Related]
9. Renin inhibitors containing psi[CH2O] pseudopeptide inserts.
TenBrink RE; Pals DT; Harris DW; Johnson GA
J Med Chem; 1988 Mar; 31(3):671-7. PubMed ID: 3279210
[TBL] [Abstract][Full Text] [Related]
10. Conformationally constrained renin inhibitory peptides: cyclic (3-1)-1-(carboxymethyl)-L-prolyl-L-phenylalanyl-L-histidinamide as a conformational restriction at the P2-P4 tripeptide portion of the angiotensinogen template.
Thaisrivongs S; Blinn JR; Pals DT; Turner SR
J Med Chem; 1991 Apr; 34(4):1276-82. PubMed ID: 2016704
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors.
Weber AE; Halgren TA; Doyle JJ; Lynch RJ; Siegl PK; Parsons WH; Greenlee WJ; Patchett AA
J Med Chem; 1991 Sep; 34(9):2692-701. PubMed ID: 1895289
[TBL] [Abstract][Full Text] [Related]
12. X-ray analysis at 2.0 A resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen.
Dealwis CG; Frazao C; Badasso M; Cooper JB; Tickle IJ; Driessen H; Blundell TL; Murakami K; Miyazaki H; Sueiras-Diaz J
J Mol Biol; 1994 Feb; 236(1):342-60. PubMed ID: 8107115
[TBL] [Abstract][Full Text] [Related]
13. Renin inhibitors. III. Synthesis and structure-activity relationships of transition-state inhibitors containing dihydroxyethylene isostere at the P1-P1 site.
Atsuumi S; Funabashi H; Nakano M; Koike Y; Tanaka S; Harada J; Matsuyama K; Ikenaga T; Morishima H
Chem Pharm Bull (Tokyo); 1994 Feb; 42(2):306-13. PubMed ID: 8149456
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of human angiotensinogen (1-17) containing one of the putative glycosylation binding sites and its hydrolysis by human renin and porcine pepsin.
Hirata IY; Boschcov P; Oliveira MC; Juliano MA; Miranda A; Chagas JR; Tsuboi S; Okada Y; Juliano L
Int J Pept Protein Res; 1991 Oct; 38(4):298-307. PubMed ID: 1797705
[TBL] [Abstract][Full Text] [Related]
15. Highly potent and specific inhibitors of human renin.
Kokubu T; Hiwada K; Murakami E; Imamura Y; Matsueda R; Yabe Y; Koike H; Iijima Y
Hypertension; 1985; 7(3 Pt 2):I8-11. PubMed ID: 2987128
[TBL] [Abstract][Full Text] [Related]
16. Substrate specificity of porcine renin: P1', P1, and P3 residues of renin substrates are crucial for activity.
Wang W; Liang TC
Biochemistry; 1994 Dec; 33(48):14636-41. PubMed ID: 7981226
[TBL] [Abstract][Full Text] [Related]
17. New inhibitors of human renin that contain novel Leu-Val replacements.
Luly JR; Yi N; Soderquist J; Stein H; Cohen J; Perun TJ; Plattner JJ
J Med Chem; 1987 Sep; 30(9):1609-16. PubMed ID: 3305946
[TBL] [Abstract][Full Text] [Related]
18. New inhibitors of human renin that contain novel replacements at the P2 site.
Doherty AM; Kaltenbronn JS; Hudspeth JP; Repine JT; Roark WH; Sircar I; Tinney FJ; Connolly CJ; Hodges JC; Taylor MD
J Med Chem; 1991 Apr; 34(4):1258-71. PubMed ID: 1901910
[TBL] [Abstract][Full Text] [Related]
19. The coexistence of Ser84 in renin and His13 in angiotensinogen brings a pH profile of two separate peaks to the reaction of human renin and sheep angiotensinogen.
Iwata H; Nakagawa T; Yoshioka Y; Kagei K; Imada K; Nakane C; Fujita H; Suzuki F; Nakamura Y
Biosci Biotechnol Biochem; 2008 Jan; 72(1):179-85. PubMed ID: 18175911
[TBL] [Abstract][Full Text] [Related]
20. Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.
Raddatz P; Minck KO; Rippmann F; Schmitges CJ
J Med Chem; 1994 Feb; 37(4):486-97. PubMed ID: 8120867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
